OSCR
Oscar Health, Inc.
OSCR has the edge over PBH overall, supported by stronger fundamentals and stronger modeled upside.
PBH
Prestige Consumer Healthcare Inc.
PBH has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PBH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Weak |
PBH's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over PBH in the historical PE scenario, which offers more potential upside but is not a forecast.
PBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.5x | $45.32 | — |
| Cheap | 13x | $41.99 | -7.4% |
| Current | 14x | $45.32 | — |
| Fair | 15x | $48.52 | +7.1% |
| Expensive | 18x | $57.31 | +26% |
Historical ranges are pointers, not guarantees.
PBH's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over PBH on the outlook, with more favorable profitability expectations.
PBH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PBH, but weaker profitability.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PBH on earnings, with more consistent year-over-year improvement.
PBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.78 | +48% |
| Q3 2026 | $3.24 | -20% |
| Q2 2026 | $3.57 | -16% |
| Q1 2026 | $3.91 | -8.9% |
| Q4 2025 | $3.78 | -11% |
| Q3 2025 | $4.03 | -1.9% |
| Q2 2025 | $4.26 | +4.2% |
| Q1 2025 | $4.29 | +2.9% |
| Q4 2024 | $4.27 | +$5.88 |
PBH earned $3.24 per share over the past year, down 20% from the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PBH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $336.3M | +23% |
| Q2 2026 | $265.7M | +6.5% |
| Q1 2026 | $281.6M | -5% |
| Q4 2025 | $283.4M | -2.4% |
| Q3 2025 | $274.1M | -3.4% |
| Q2 2025 | $249.5M | -6.6% |
| Q1 2025 | $296.5M | +7% |
| Q4 2024 | $290.3M | +2.7% |
PBH's revenue has picked up after four years of holding roughly level: $336M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.1 points |
| Q2 2026 | 20% | -9 points |
| Q1 2026 | 27% | -3 points |
| Q4 2025 | 29% | -2.6 points |
| Q3 2025 | 29% | -0.7 points |
| Q2 2025 | 29% | +1.8 points |
| Q1 2025 | 30% | +0.2 points |
| Q4 2024 | 32% | +1 points |
PBH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PBH on cash flow, with more consistent year-over-year improvement.
PBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.2M | -38% |
| Q2 2026 | $67.1M | -14% |
| Q1 2026 | $37.6M | -36% |
| Q4 2025 | $75.3M | +18% |
| Q3 2025 | $55.4M | -18% |
| Q2 2025 | $78.2M | +46% |
| Q1 2025 | $58.4M | -8.5% |
| Q4 2024 | $63.5M | -8.6% |
PBH's free cash flow has been positive every quarter for seven years: $214M over the past year, down 16% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -11K shares |
| 1 year | -3.4% | -1.7M shares |
| 3 years | -5% | -2.5M shares |
| 5 years | -6.3% | -3.2M shares |
| Available history | -6.4% | -3.2M shares |
PBH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $690,000 |
| Q4 2025 | $45.8M |
| Q3 2025 | $75M |
| Q2 2025 | $34.8M |
| Q1 2025 | $11.3M |
| Q4 2024 | $2.4M |
PBH spent $47M buying back its own shares over the past year, down 62% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PBH on leverage, with a lower net debt burden relative to earnings.
PBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.2x | High |
| Q2 2026 | 6.0x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 2.6x | Moderate |
PBH's net debt is about 6.2 years of its operating earnings (EBITDA), up from 2.4 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 25.2 | Neutral |
PBH's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over PBH on valuation relative to its sector.
PBH PE vs Healthcare Sector
| Metric | PBH | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 46% below |
| PE % | 29 | 29 | Same percentile |
PBH is trading at 14x earnings, a 46% discount to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PBH on trend strength, trading above more of its moving averages.
PBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 3.4% below |
| 20 week MA | $48.9 | 7.3% below |
| 50 week MA | $54.7 | 17% below |
| 100 week MA | $65.0 | 30% below |
| 200 week MA | $65.3 | 31% below |
PBH is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PBH on returns for 2026, with the stronger performance.
PBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $34.9 | -14% |
| 2021 | $34.9 | $61.9 | +77% |
| 2022 | $61.9 | $62.0 | +0.2% |
| 2023 | $62.0 | $61.2 | -1.3% |
| 2024 | $61.2 | $78.5 | +28% |
| 2025 | $78.5 | $62.8 | -20% |
| 2026 YTD | $62.8 | $45.3 | -28% |
PBH has finished lower in three of the last six years. It's down 28% so far in 2026.